Head to head
Stepan vs Linde
Side-by-side on the measures that matter, with a plain-English read. Full detail: SCL · LIN
SCL
Stepan
63.48-2.34%
1-year price shape — +53% over the period
Quant Rating C · 89/100
vs
LIN
Linde
502.83-1.45%
1-year price shape — +25% over the period
Quant Rating C · 69/100
1-year performance, rebased to 100
Linde edges it on the scoreable measures. Linde trades cheapest on trailing earnings; Linde earns the most per share.
| SCL | LIN | |
|---|---|---|
| Snapshot | ||
| Sector | Specialty Chemicals | Specialty Chemicals |
| Last price | 63.48 | 502.83 |
| Change today | -2.34% | -1.45% |
| 1-year return | +53.4% | +24.8% |
| Market cap | $1.44B | $230.84B |
| 52-week range | 41.71 – 72.67 | 384.00 – 546.40 |
| Valuation | ||
| P/E (TTM) | 334.11 | 33.39 |
| P/E percentile, own 5-yr range | 99th | 57th |
| P/B | 1.18 | 5.86 |
| Dividend yield | 2.49% | 1.25% |
| Profitability & growth | ||
| EPS (TTM) | 2.05 | 14.61 |
| Net profit (TTM) | $46.61M | $6.71B |
| Revenue (TTM) | $2.53B | $36.24B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +17.3% | +9.2% |
| Gross margin | 12.0% | 47.9% |
| Operating margin | 3.6% | 27.1% |
| Net margin | 0.2% | 19.3% |
| Free cash flow (TTM) | $4.56M | $5.08B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 91.9% | 88.6% |
| Insider activity (12mo) | 24 buy / 12 sell | 27 buy / 16 sell |
| Short interest (% of float) | 3.0% | 1.4% |
| Analyst consensus | 100% buy (1) | 94% buy / 6% hold (16) |
| Analyst price target | $85 (+34%) | $570 (+13%) |
| StockVane view | ||
| StockVane Quant Rating | C (89) | C (69) |
| Company | ||
| Employees | 2,328 | 65,177 |
| Founded | 1932 | 2017 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.